Novo Nordisk Juggles Lilly's Clinical Challenge and Wegovy's Indian Opportunity

The Danish drugmaker ended last week with a stock that barely budged, yet the forces pulling it in opposite directions have rarely been clearer. Eli Lilly’s latest clinical data threaten the competitive moat in Novo Nordisk’s core GLP-1 business, while a regulatory green light for Wegovy in India opens a fresh geographic channel. For investors, the question is whether expansion can outrun the pricing and efficacy headwinds.

Novo Nordisk shares closed Friday at €39.05 in Frankfurt, essentially flat on the day. The stock has managed a 0.8% weekly gain and stands comfortably above its 50-day moving average of €35.27. But the broader picture remains bruised: year-to-date losses stand at 12.6%, and the shares are down nearly 36% from a year ago. The price also trails its 200-day line by 6.9%, signalling that the recovery is still fragile.

Lilly’s Data Puts Efficacy Front and Centre

The latest blow comes from Eli Lilly's SURPASS-EARLY trial, which enrolled nearly 800 adults diagnosed with type 2 diabetes within the previous four years. After two years, about 60% of patients receiving tirzepatide achieved normal blood glucose levels, compared with just 24% in the control group — which largely consisted of patients on other GLP-1 therapies, including Novo Nordisk’s own semaglutide products.

The data strike at the heart of Novo Nordisk’s franchise. GLP-1 medicines are the engine of its growth, and Lilly has now produced a head-to-head signal of superiority in a population that matters for early disease management. While the study does not directly compare tirzepatide with semaglutide in a randomised fashion against Novo’s specific drugs, the gap is wide enough to sharpen the competitive narrative. Novo Nordisk will need to show that its pipeline — including oral formulations and next-generation candidates — can close the efficacy gap.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

India Approval Adds a Younger Demographic

On the same week that the Lilly data emerged, Novo Nordisk secured a different kind of win. India’s drug regulator has approved Wegovy for adolescents aged 12 and older who weigh more than 60 kilograms, for weight management alongside diet and exercise. The decision extends Wegovy’s label beyond the core adult population and gives Novo a foothold in a market where Lilly’s Mounjaro currently outsells Wegovy among injectables.

The immediate revenue impact from the adolescent segment is unlikely to move the needle for a company of Novo’s size. But the approval carries strategic weight. It signals that the company is defending its GLP-1 franchise through broader indications and differentiated label profiles at a time when pricing pressure and fierce competition are eroding margins. Every incremental regulatory advantage matters when the market is watching for signs of erosion.

Buybacks Keep the Capital Story Alive

Alongside commercial moves, Novo Nordisk continues to support its stock through share repurchases. The current programme, announced in May, allows for up to 11.2 billion Danish kroner in B-share buybacks as part of a larger framework of 15 billion kroner over 12 months, running until February 2027. As of May 22, the company had bought back 17,049,028 B-shares at an average price of 262.22 kroner, for a total outlay of 4.47 billion kroner. It now holds 34.2 million B-shares in treasury, or about 0.8% of total share capital.

Buybacks do not substitute for organic growth, but they help stabilise returns and offset some of the dilution from employee programmes. In a period when earnings visibility is low, the repurchase programme provides a floor.

Q1 Results and the 2026 Outlook Reveal the Tension

The underlying conflict in the Novo Nordisk story came into sharp relief with the first-quarter report. Adjusted for a one-off 340B effect of $4.2 billion, revenues fell 4% year-on-year in currency-adjusted terms, even as obesity medicine sales climbed 22%. The disconnect illustrates the core problem: strong volume demand for GLP-1 drugs is being eaten away by lower realised prices in the US market.

Management’s guidance for 2026 does little to soothe nerves. The company expects adjusted revenue and operating profit to decline by 4% to 12% on a currency-adjusted basis. That forecast, published in the Q1 release, incorporates the expectation that price pressure will persist.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

Medical data from the POSEIDON observational study, which tracked 18,904 patients across 18 countries, further underscores the complexity of the field. It found that cardiovascular inflammation remains widespread despite standard therapy. Among patients with atherosclerotic cardiovascular disease and chronic kidney disease, two in five had hsCRP levels of at least 2 mg/L — a signal that GLP-1 drugs with anti-inflammatory properties could have a role beyond glucose and weight control. But that is a long-term opportunity, not an immediate remedy.

Analysts Stay Cautious

Jefferies analyst Michael Leuchten maintains a neutral rating on the stock with a price target of 270 Danish kroner. That target is below the latest close of the B-share in Copenhagen at 292.95 kroner, implying that the recent bounce has run ahead of fundamentals. Leuchten’s stance reflects the structural risks that the Lilly trial and the Q1 results have brought to the surface.

For Novo Nordisk, the path forward hinges on whether additional regulatory approvals, volume growth, and buybacks can collectively outweigh the margin erosion from pricing and competition. The India decision strengthens the product story; the Lilly trial weakens the competitive narrative. Until the company can demonstrate that its pipeline and geographic expansion can deliver sustainable earnings growth, the stock’s story will remain split between a strong medical franchise and a difficult profit lever.

Ad

Novo Nordisk Stock: New Analysis - 30 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69446557 |